ARQT: Arcutis Biotherapeutics, Inc. Stock

by  •  • Comments Off on ARQT: Arcutis Biotherapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,713.20
Enterprise Value ($M) 1,767.72
Book Value ($M) 142.66
Book Value / Share 1.20
Price / Book 12.01
NCAV ($M) 122.22
NCAV / Share 1.03
Price / NCAV 14.02

Profitability (mra)
Return on Invested Capital (ROIC) -0.51
Return on Assets (ROA) -0.27
Return on Equity (ROE) -0.58

Liquidity (mrq)
Quick Ratio 3.37
Current Ratio 3.55

Balance Sheet (mrq) ($M)
Current Assets 323.67
Assets 344.11
Liabilities 201.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 196.54
Operating Income -128.40
Net Income -140.04

Cash Flow Statement (mra) ($M)
Cash From Operations -112.16
Cash from Investing 28.82
Cash from Financing 66.20

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-15 13G/A Prudential Financial Inc 10.10 20.94
05-15 13G/A Polar Capital Holdings Plc 5.65 6.49
05-08 13G/A Jennison Associates Llc 9.60 -6.33
11-14 13G/A Point72 Asset Management, L.P. 0.20 -94.92
11-13 13G/A Rubric Capital Management LP 9.38 65.05
11-08 13G/A BlackRock, Inc. 7.70 0.00
11-06 13G/A Morgan Stanley 3.40 -34.46

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-07-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-06 374,603 2,131,845 17.57
2025-06-05 170,038 1,012,461 16.79
2025-06-04 157,125 999,982 15.71
2025-06-03 164,982 1,109,924 14.86
2025-06-02 213,942 1,346,789 15.89

(click for more detail)

Similar Companies
ANAB – AnaptysBio, Inc. ANNX – Annexon, Inc.
APLS – Apellis Pharmaceuticals, Inc. ARVN – Arvinas, Inc.
ARWR – Arrowhead Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io